INSM - Insmed Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
30.45
-0.48 (-1.55%)
As of 2:40PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close30.93
Open30.83
Bid30.43 x 1400
Ask30.49 x 1300
Day's Range30.05 - 30.86
52 Week Range11.31 - 33.13
Volume433,091
Avg. Volume801,587
Market Cap2.363B
Beta (3Y Monthly)4.09
PE Ratio (TTM)N/A
EPS (TTM)-4.22
Earnings DateApr 30, 2019 - May 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est42.10
Trade prices are not sourced from all markets
  • Estimating The Intrinsic Value Of Insmed Incorporated (NASDAQ:INSM)
    Simply Wall St.9 days ago

    Estimating The Intrinsic Value Of Insmed Incorporated (NASDAQ:INSM)

    How far off is Insmed Incorporated (NASDAQ:INSM) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the foreast future cash flows of the company and dis...

  • Insmed Granted Additional U.S. Patent For ARIKAYCE® (amikacin liposome inhalation suspension), Strengthening Brand's Global Patent Portfolio
    PR Newswire16 days ago

    Insmed Granted Additional U.S. Patent For ARIKAYCE® (amikacin liposome inhalation suspension), Strengthening Brand's Global Patent Portfolio

    BRIDGEWATER, N.J., April 9, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued patent No. 10,251,900 for certain uses of ARIKAYCE (amikacin liposome inhalation suspension). The claims of the patent relate in part to methods for treating Mycobacterium avium complex (MAC) lung disease via administration of ARIKAYCE to patients previously unresponsive to MAC therapy. This is the 10th patent issued by the USPTO for ARIKAYCE in MAC lung disease and the second with an expiry date of May 15, 2035.

  • Insmed Provides Update on ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Launch
    PR Newswire17 days ago

    Insmed Provides Update on ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Launch

    BRIDGEWATER, N.J., April 8, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today provided an update on the U.S. launch of ARIKAYCE® (amikacin liposome inhalation suspension), including preliminary net product sales for the first quarter of 2019.  ARIKAYCE was granted accelerated approval by the U.S. Food and Drug Administration (FDA) on September 28, 2018, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients who have limited or no alternative treatment options. "We continue to be very pleased with the U.S. launch progress of ARIKAYCE and the positive feedback received from the refractory MAC lung disease community," said Will Lewis, Chairman and Chief Executive Officer of Insmed.

  • Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    PR Newswire23 days ago

    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BRIDGEWATER, N.J., April 2, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 12 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company. In connection with the commencement of their employment, the employees received options on April 1, 2019 to purchase an aggregate 26,260 shares of Insmed common stock at an exercise price of $29.09 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.

  • Insmed To Showcase New ARIKAYCE® (amikacin liposome inhalation suspension) And Pipeline Data At American Thoracic Society International Conference
    PR Newswire24 days ago

    Insmed To Showcase New ARIKAYCE® (amikacin liposome inhalation suspension) And Pipeline Data At American Thoracic Society International Conference

    BRIDGEWATER, N.J., April 1, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that new Phase 3 data for ARIKAYCE® (amikacin liposome inhalation suspension) in Mycobacterium avium complex (MAC) lung disease will be presented as a late-breaker at the American Thoracic Society (ATS) International Conference, May 17-22, in Dallas. Additional data on ARIKAYCE as well as on Insmed's pipeline candidates will also be presented at the meeting.

  • Insmed to Present at the H.C. Wainwright Global Life Sciences Conference
    PR Newswire24 days ago

    Insmed to Present at the H.C. Wainwright Global Life Sciences Conference

    BRIDGEWATER, N.J., April 1, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Will Lewis, Chairman and Chief Executive Officer of Insmed, will present at the H.C. Wainwright Global Life Sciences Conference in London on Monday, April 8, 2019 at 10:50 a.m. BST. Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases.

  • Insmed Announces Management Changes
    PR Newswire29 days ago

    Insmed Announces Management Changes

    BRIDGEWATER, N.J. , March 27, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...

  • Markit2 months ago

    See what the IHS Markit Score report has to say about Insmed Inc.

    Insmed Inc NASDAQ/NGS:INSMView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is moderately high for INSM with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative but appears to be improving. Over the last one-month, outflows of investor capital in ETFs holding INSM totaled $75 million. However, outflows appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of INSM earnings conference call or presentation 22-Feb-19 1:30pm GMT

    Q4 2018 Insmed Inc Earnings Call

  • Insmed Inc (INSM) Q4 2018 Earnings Conference Call Transcript
    Motley Fool2 months ago

    Insmed Inc (INSM) Q4 2018 Earnings Conference Call Transcript

    INSM earnings call for the period ending December 31, 2018.

  • Insmed (INSM) Reports Q4 Loss, Tops Revenue Estimates
    Zacks2 months ago

    Insmed (INSM) Reports Q4 Loss, Tops Revenue Estimates

    Insmed (INSM) delivered earnings and revenue surprises of -5.41% and 96.19%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Insmed: 4Q Earnings Snapshot

    On a per-share basis, the Bridgewater, New Jersey-based company said it had a loss of $1.19. Losses, adjusted for amortization costs, were $1.17 per share. The results fell short of Wall Street expectations. ...

  • Insmed Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
    PR Newswire2 months ago

    Insmed Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

    --ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Net Product Sales of $9.2 Million for the Fourth Quarter and Full Year 2018-- --Company Provides Full-Year 2019 ARIKAYCE Revenue Guidance of $80 ...

  • Insmed to Present at the Leerink Partners 8th Annual Global Healthcare Conference
    PR Newswire2 months ago

    Insmed to Present at the Leerink Partners 8th Annual Global Healthcare Conference

    BRIDGEWATER, N.J., Feb. 20, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Will Lewis, Chairman and Chief Executive Officer of Insmed, will present at the Leerink Partners 8th Annual Global Healthcare Conference in New York on Wednesday, February 27, 2019 at 3:30 p.m. ET. Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases.

  • Insmed to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call on Friday, February 22, 2019
    PR Newswire2 months ago

    Insmed to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call on Friday, February 22, 2019

    BRIDGEWATER, N.J. , Feb. 15, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that ...

  • Is Insmed Incorporated’s (NASDAQ:INSM) Balance Sheet Strong Enough To Weather A Storm?
    Simply Wall St.2 months ago

    Is Insmed Incorporated’s (NASDAQ:INSM) Balance Sheet Strong Enough To Weather A Storm?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Small-cap and large-cap companies receive a lotRead More...

  • GlobeNewswire3 months ago

    Market Trends Toward New Normal in lululemon athletica inc, Insmed, Advanced Disposal Services, AGCO, Douglas Dynamics, and Ballard Power — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Feb. 07, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Options Traders Expect Huge Moves in Insmed (INSM) Stock
    Zacks3 months ago

    Options Traders Expect Huge Moves in Insmed (INSM) Stock

    Investors need to pay close attention to Insmed (INSM) stock based on the movements in the options market lately.

  • Benzinga3 months ago

    Top 5 Small-Cap Winners And Losers, Week Of Jan. 7

    In today’s round-up of the previous week’s top five shakers and fakers (i.e. winners and losers,), we see some major jumps or drops depending on how well company announcements were received. For some, ...

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Fool3 months ago

    3 Biotech Stocks That Soared This Week: Are They Buys?

    These biotech stocks jumped 31% or more over the last few days. Can their momentum continue?